Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

All Specialties

OpiCalc Logo
FavoritesSpecialtiesDrugsGuidelinesMost Used
FavesSpecsDrugsGuidesTop
ALBI Grade (Liver)ASTCT GradingATA Thyroid RiskBCLC 2022 Staging (HCC)BSA (Mosteller)CLL-IPICML ELTS ScoreCNS-IPICTCAE v5.0Calvert FormulaDIPSS-Plus (Myelofibrosis)Deauville ScoreEAU NMIBC RiskECOG Performance StatusELN 2022 Risk (AML)ELN CML MilestonesFIGO 2021 (Ovarian)FIGO 2023 (Endometrial)FLIPI-2Fleischner 2017 GuidelinesFong Clinical Risk ScoreHCT-CI (Sorror Score)HPV/p16 OropharynxIGCCCG Risk (Testicular)IMDC (Heng) CriteriaIMWG Myeloma FrailtyIPSS-M (Molecular MDS)ISUP Grade GroupsKarnofsky Status (KPS)Khorana ScoreLugano ClassificationLung-RADS v2022MIPI-b (Biological)MRD Assessment FrameworkMSI/MMR InterpretationMayo 20/2/20 (SMM)NCCN Prostate RiskNCCN-IPI (DLBCL)NSCLC GPAOncotype DX RecurrenceOpioid EquianalgesicPD-L1 TPS InterpretationPERCIST 2.0PREDICT v3.0Platinum-Free IntervalR2-ISS (Revised 2)RANO 2.0RCB (Residual Cancer Burden)RECIST 1.1ROMA ScoreSAVER ScoreSINS ScoreSLiM-CRAB CriteriaSedlis/Peters CriteriaTNM 8th (Colorectal)TNM 8th Ed (Prognostic)TNM 9th (Nasopharynx)TNM 9th Ed (NSCLC)TNM 9th Ed (SCLC)Tyrer-Cuzick (IBIS v8)WHO 2021 CNS Class.WHO 2022 / ICC 2022 AMLZ0011 EligibilityiRECISTiwCLL 2018 ResponsemRECIST (HCC)mRENAL ScoremrTRG (Rectal MRI)
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2018-2026

•

All Rights Reserved

Recent Journal Updates

Intensive Care MedicineJun 8, 2026
International evidence-based recommendations for point-of-care lung ultrasound

Clinical Context

We think this might be relevant to the clinical guidance for IMDC (Heng) Criteria for Metastatic RCC.

CancerJun 5, 2026
Executive summary of American Radium Society Appropriate Use Criteria for the treatment of locoregionally recurrent rectal cancer

Clinical Context

We think this might be relevant to the clinical guidance for IMDC (Heng) Criteria for Metastatic RCC.

DiabetologiaMay 22, 2026
Age-related patterns of cardiometabolic risk factors for complications in type 2 diabetes

Clinical Context

We think this might be relevant to the clinical guidance for IMDC (Heng) Criteria for Metastatic RCC.

IMDC (Heng) Criteria

IMDC (HENG)Risk Stratification for Metastatic RCC

Prognostic Tier

Scoring Definition

  • Favorable: 0 risk factors.
  • Intermediate: 1-2 risk factors.
  • Poor: 3-6 risk factors.

Treatment Impact

Favorable Risk

Clinical Strategy

Favorable risk group. First-line therapy often includes TKI monotherapy (e.g., Sunitinib, Pazopanib) or TKI/IO combinations.

Guidelines & Evidence

Verified

Last Review: 2026

When to Use

Clinical Use

All patients with metastatic clear-cell Renal Cell Carcinoma (RCC).
To guide frontline treatment selection between doublet immunotherapy (IO/IO) and IO/TKI combinations.
Requires KPS, Hemoglobin, Corrected Calcium, Neutrophils, Platelets, and time from diagnosis to treatment.

Related Scores in Practice

In clinical practice, this assessment is frequently evaluated alongside other validated measures. Depending on the patient's presentation and specific diagnostic requirements, you may also need to utilize the mRENAL Score, IGCCCG Risk (Testicular) or the CTCAE v5.0 to formulate a comprehensive care plan.

Last Comprehensive Review: 2026

Related Oncology Tools

mRENAL Score
IGCCCG Risk
CTCAE v5.0
SINS Score
Lugano Classification
Khorana Score
TNM 8th
CNS-IPI
Z0011 Eligibility
Fong Clinical Risk Score
Oncology CalculatorsInternal Medicine CalculatorsEmergency Medicine Calculators
Have feedback about this calculator?Let us know.